RxDoctor Payments Data

Frantz Alphonse

Medical · Tumwater, WANPI 1811345762

Payments from drug & device makers

$930in general payments, 2019–2025

Across 37 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$432
  • Otsuka America Pharmaceutical, Inc.$130
  • Alkermes, Inc.$121
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • Neurocrine Biosciences, Inc.$58
  • Teva Pharmaceuticals USA, Inc.$38
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 75th percentile of 457 medical providers in Washington.

See all medical providers in Washington

Medicare billing

Part B allowed, 2024
$77,856
Medicare patients
282
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$43,361
OzempicSemaglutide35$36,971
XareltoRivaroxaban32$22,756
Xtampza ErOxycodone Myristate21$11,727
Aimovig AutoinjectorErenumab-Aooe12$10,723
OxycontinOxycodone Hcl14$7,317
Gabapentin238$6,470
Advair HfaFluticasone Propion/Salmeterol14$4,991
VascepaIcosapent Ethyl14$4,500
Oxycodone Hcl146$4,281
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$4,011
Baclofen126$3,692
Cyclobenzaprine Hcl135$3,041
Hydromorphone Hcl27$3,011
Pantoprazole Sodium101$2,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$432$22,75632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 457 medical providers in Washington.

Other medical in Tumwater

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →